WUHAN, China, March 12, 2018 /PRNewswire/ -- XW Laboratories Inc. (XW Labs) announced the initiation of a Phase 1 single ascending dose (SAD) study in healthy subjects for its novel proprietary lead compound XW10172 to assess safety, tolerability and pharmacokinetics. XW10172 is the lead compound in XW Labs' pipeline for a next generation small molecule treatment for narcolepsy, a rare chronic neurological disorder which affects sleep regulation. XW Labs intends to begin a multiple ascending dose study pending satisfactory outcome of the initial doses from the SAD study.
XW Labs' drug discovery team identified XW10172 through its efforts to create a narcolepsy treatment that exhibits favorable efficacy compared to existing first-line treatments but with better compliance and tolerability. Narcolepsy is a sleep disorder with abnormal regulation of the sleep-wake cycle. Patients with narcolepsy type 1 typically present with excessive daytime sleepiness (EDS) and cataplexy among other symptoms. Most currently available treatments of narcolepsy target one symptom and those treating both EDS and cataplexy may be associated with intolerable side effects or inconvenient dosing regimen. XW10172 is a novel agent that is expected not only to be efficacious in treating the primary symptoms of narcolepsy but also improve the tolerability and dosing convenience.
